Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
Lupsa BC, Inzucchi SE. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia 2018, 61: 2118-2125. PMID: 30132031, DOI: 10.1007/s00125-018-4663-6.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsBenzhydryl CompoundsBlood GlucoseBlood PressureBody WeightBone and BonesCanagliflozinCardiovascular DiseasesDiabetes Mellitus, Type 2Diabetic KetoacidosisGlucosidesHumansHypoglycemic AgentsKetosisKidneyNeoplasmsRandomized Controlled Trials as TopicRisk AssessmentSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsWeight LossConceptsSGLT2 inhibitorsSodium-glucose cotransporter 2 inhibitorsPostprandial blood glucose levelsEuglycaemic diabetic ketoacidosisGlucose-lowering medicationsCotransporter 2 inhibitorsDiabetic kidney diseaseGenitourinary tract infectionsLower extremity amputationHigh-risk individualsBlood glucose levelsPlasma glucose concentrationCardiovascular outcomesDiabetic ketoacidosisUrinary frequencyTract infectionsOptimal prescribingNew drug categoryKidney diseaseGlucose reabsorptionGlucose levelsHigh riskDrug categoriesBody weightBone fractures
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply